Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Burundi, Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Achieving Lumbar Punctures Meet the Guidelines and an Introduction 15 Days of Antiretroviral Therapy

X
Trial Profile

Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Burundi, Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Achieving Lumbar Punctures Meet the Guidelines and an Introduction 15 Days of Antiretroviral Therapy

Status: Suspended
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluconazole (Primary) ; Flucytosine (Primary) ; Antiretrovirals
  • Indications Cryptococcal meningitis; HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2016 Biomarkers information updated
    • 10 Jul 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 04 Dec 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top